UCB, Roche to develop antibodies for Alzheimer's disease
Biopharmaceutical firm UCB has signed a deal to provide Roche and Genentech with an exclusive, worldwide license to its UCB0107 antitau antibody treatment for people living with Alzheimer's disease. Read More
Omega Therapeutics advances epigenomic programming platform
Omega Therapeutics has received $85 million in financing to support clinical trials of its epigenomic controllers for programs in oncology, inflammation, autoimmune, metabolic, and rare genetic diseases. Read More
Truebinding licenses gene-editing platform from Horizon Discovery
TrueBinding has signed a set of commercial licenses for the use of Horizon Discovery's current good manufacturing practice-compliant Chosource platform. Read More
Avacta, Daewoong partner on COVID-19 therapy
Avacta has expanded its collaboration with Daewoong Pharmaceutical to develop stem cell treatments using Avacta's neutralizing Affimer therapy for COVID-19 patients. Read More
Constant Therapeutics to begin U.S. phase II clinical trial of COVID-19 therapy
Constant Therapeutics will begin a phase II clinical trial of the peptide drug TXA127 at Columbia University Irving Medical Center in New York City for the treatment of COVID-19. Read More
ASU, World Economic Forum launch business survey for COVID-19
Arizona State University (ASU) and the World Economic Forum have launched COVID-19 Diagnostics Commons, a project that will survey businesses and share knowledge about how to safely and effectively bring employees back to work. Read More
Soligenix advances COVID-19 vaccine
Biopharmaceutical firm Soligenix said that preclinical immunogenicity studies of its CiVax heat stable subunit COVID-19 vaccine candidate demonstrated that both broad-spectrum antibody immunity and cell-mediated rapid onset immunity are possible using the CoVaccine HT adjuvant. Read More
ExeVir wins backing to develop llama-derived antibodies for COVID-19
Belgian firm ExeVir Bio has closed on a 23 million euro ($26.9 million U.S.) series A financing round to support the development of its llama-derived antibody technology in treating COVID-19. Read More
Recursion acquires Vium for drug discovery
Recursion has acquired Vium to advance its technologies and grow its drug discovery pipeline of over 30 programs. Read More
Schrodinger, Viva collaborate on structure-based drug discovery
Schrodinger and Viva Biotech have entered a strategic collaboration to expand structure-based drug discovery by generating de novo crystal structures of high-value targets. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
